Glanbia plc GLAPF

Key data

The business

Glanbia is two companies wearing one ticker. The first, and the reason to own it, is Performance Nutrition: protein powder and bars sold under brand names the company states include Optimum Nutrition, plus a set of other brands in the category. A tub of Gold Standard Whey costs more than the store brand next to it on the shelf and sells anyway, which is the whole moat in one sentence: a brand people trust enough to pay up for. The second is Nutritional Solutions, an ingredients arm that sells protein systems, premixes and bioactives to other food makers. Bolted on for years was a big, thin-margin US cheese operation, and management is now deconsolidating it. That is why revenue is falling while profit is not: they are selling the low-quality pounds and keeping the high-quality ones. What you are buying, stripped down, is a branded protein compounder that happens to still be shedding a commodity skin.

The numbers

Glanbia reports twice a year, so the honest unit is the half. The adjusted profit per share for the last four halves tells the story cleanly, and it is a story of earnings that keep landing above what was penciled in:

H1 2026 is the inflection: $0.81 against $0.63 a year earlier, up 29%, and the widest gap over estimate in the set. That directly answers the question left hanging in early September, whether the whey input-cost line and unit-level margin would bite: they eased rather than bit, with pricing and mix carrying earnings up while gross margin held near 26%. Whey is still expensive, so this is recovery, not relief.

The forward line is where the tension lives. Consensus does not expect much:

From FY2025 to FY2028 the Street models earnings up about 15% total, roughly 5% a year, because it is watching revenue shrink from about $4.1B to $3.75B and extrapolating a fading business. But that revenue line is the cheese leaving, not the brand slowing. Underneath, first-half branded earnings grew four to five times faster than the modeled full-year rate. The variant this memo holds: the market is pricing the whole company off the falling top line when the part that matters is compounding double digits, and the print that settles it is the Performance Nutrition volume-and-margin split at the February 2027 full-year report. If branded volume is positive and gross margin is up, the low forward estimates are wrong.

The valuation carries the same double image. On depressed reported earnings, dragged down by deconsolidation charges, the multiple is about 35 times, the top of a twelve-year range that has usually run 17 to 22 times. On adjusted forward earnings it is about 19 times. Which number is real depends entirely on whether you believe the cheese exit is a one-time cleanup or a permanent hole.

Management

The company reports a CEO whose name was not independently verified this run. Capital return is steady and shareholder-friendly, a running buyback layered on the dividend, and the buybacks are being funded partly by the cash freed from selling the cheese assets, which is the right trade if the remaining business is worth more per share concentrated. Insider open-market activity in the trailing twelve months: zero transactions recorded, zero dollars of buys or sells. The record to trust is the six straight halves of meeting or clearing estimates, not a bio.

How it fails or surprises you

The revenue is genuinely shrinking (the fact the read explains least). Consensus revenue falls from about $4.1B to $3.75B. My read says that is all cheese leaving. If even a third of it is Optimum Nutrition losing shelf to cheaper protein or to smaller appetites, the earnings-growth case is a story about accounting, not demand. The February 2027 branded volume line proves or breaks it.

Whey spikes and margin gives back the gains. Gross margin sits near 26% with whey already elevated. A 200 basis-point input-cost move on roughly $4B of sales is about $80M of pretax profit, enough to erase a year of the earnings growth the multiple assumes. Watch dairy input indices into H2 2026.

GLP-1 turns into a tailwind, not a threat (right tail). Weight-loss drugs cut how much people eat but raise how much protein they need to keep muscle. If Optimum Nutrition captures that prescription-driven protein demand, GPN volume re-accelerates from low single digits toward double, and the 19x forward multiple looks like the wrong anchor. The market is paying for none of this today; the first sign is GPN volume outrunning price at the interims.

Closing thoughts

The February 2027 full-year report settles this. The one number that decides the stock is the Performance Nutrition volume-and-margin disclosure: a positive branded volume with firm gross margin converts the low forward estimates into obviously-too-low, an ambiguous print leaves you paying a full multiple for a company that still looks like it is shrinking, and if that happens you wait for the next half rather than pay up. The fatter tail is up, because the thing suppressing the headline, the cheese exit, is finite and disclosed, while the thing that could surprise, protein demand, is open-ended. What is at risk if whey spikes is roughly a year of earnings growth; what the right tail is worth is a re-rating of the whole branded business the market is currently valuing as ex-growth.

The bet is still that people keep buying more protein powder and protein bars and keep paying up for Optimum Nutrition, and that whey does not spike and eat the profit. It breaks if branded volume goes flat while gross margin slips, and the one pair of numbers that tells you first is GPN volume growth set against gross margin at the next full-year report. If both roll over together, the cheese was not the problem.